EMERYVILLE, Calif., August 4 /PRNewswire-FirstCall/ -- Bionovo, Inc. today announced positive results from the Phase 1B clinical trial of Bezielle (formerly BZL101), their lead drug candidate for advanced breast cancer. In the trial, Bezielle showed an excellent safety and tolerability profile, and also showed promising indications of efficacy in a difficult-to-treat population.
